Compare W & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | W | RDY |
|---|---|---|
| Founded | 2002 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 11.8B |
| IPO Year | 2014 | 2001 |
| Metric | W | RDY |
|---|---|---|
| Price | $87.86 | $11.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 1 |
| Target Price | ★ $105.82 | $16.90 |
| AVG Volume (30 Days) | 2.8M | ★ 2.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 39.15 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.39 | $7.72 |
| Revenue Next Year | $6.00 | $3.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $55.60 | $11.36 |
| 52 Week High | $119.98 | $15.67 |
| Indicator | W | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 32.45 |
| Support Level | $84.24 | $11.36 |
| Resistance Level | $95.82 | $14.08 |
| Average True Range (ATR) | 4.20 | 0.27 |
| MACD | -0.42 | -0.07 |
| Stochastic Oscillator | 46.55 | 27.67 |
Wayfair engages in e-commerce in the United States (88% of 2025 sales), Canada, the United Kingdom, and Ireland. It's also embarked on expansion into the brick-and-mortar landscape, with 13 stores (excluding outlets) between the AllModern, Birch Lane, Joss & Main, and Wayfair banners. At the end of 2025, the firm offered more than 40 million products from more than 20,000 suppliers under the brands Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold. Its offerings include furniture, everyday and seasonal decor, decorative accents, housewares, as well as advertising and logistics services. Wayfair was founded in 2002 and began trading publicly in 2014.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.